Literature DB >> 30539471

One-Tube Multicolor Flow Cytometry Assay (OTMA) for Comprehensive Immunophenotyping of Peripheral Blood.

Anna-Jasmina Donaubauer1, Paul F Rühle1, Ina Becker1, Rainer Fietkau1, Udo S Gaipl2, Benjamin Frey1.   

Abstract

Recent improvements in the flow cytometry technology allow the determination of the general immune status through the development of multicolor immunofluorescence panels. The one-tube multicolor flow cytometry assay (OTMA) that is presented here identifies 20 different, clinically relevant immune cell subsets and three common activation markers. Thereby, a comprehensive immune status that covers all major immune cells is easily obtained.The assay is suitable for every common three lasers and 10 color flow cytometer and includes the application of 15 different antibodies. Furthermore, the assay requires only 100 μL of EDTA-treated whole-blood and less than 40 min for sample preparation. By being easily adaptable to individual requirements and by additionally determining absolute cell counts, the assay is well-suited for translational research in clinical trials.

Entities:  

Keywords:  Absolute cell count; Antibody; Gating strategy; Human whole-blood; Immune status; Immunophenotyping; Multicolor flow cytometry; One-tube measurement

Mesh:

Substances:

Year:  2019        PMID: 30539471     DOI: 10.1007/978-1-4939-8958-4_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.

Authors:  Jian-Guo Zhou; Anna-Jasmina Donaubauer; Udo Gaipl; Markus Hecht; Benjamin Frey; Ina Becker; Sandra Rutzner; Markus Eckstein; Roger Sun; Hu Ma; Philipp Schubert; Claudia Schweizer; Rainer Fietkau; Eric Deutsch
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

2.  Low Dose Radiation Therapy Induces Long-Lasting Reduction of Pain and Immune Modulations in the Peripheral Blood - Interim Analysis of the IMMO-LDRT01 Trial.

Authors:  Anna-Jasmina Donaubauer; Ina Becker; Thomas Weissmann; Birgitta M Fröhlich; Luis E Muñoz; Thomas Gryc; Manuel Denzler; Oliver J Ott; Rainer Fietkau; Udo S Gaipl; Benjamin Frey
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

3.  Anti-inflammatory effects of an autologous gold-based serum therapy in osteoarthritis patients.

Authors:  Jessica Feldt; Anna-Jasmina Donaubauer; Jessica Welss; Ulrich Schneider; Udo S Gaipl; Friedrich Paulsen
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.379

4.  Development of a standardized and validated flow cytometry approach for monitoring of innate myeloid immune cells in human blood.

Authors:  Kyra van der Pan; Sandra de Bruin-Versteeg; Daniela Damasceno; Alejandro Hernández-Delgado; Alita J van der Sluijs-Gelling; Wouter B L van den Bossche; Inge F de Laat; Paula Díez; Brigitta A E Naber; Annieck M Diks; Magdalena A Berkowska; Bas de Mooij; Rick J Groenland; Fenna J de Bie; Indu Khatri; Sara Kassem; Anniek L de Jager; Alesha Louis; Julia Almeida; Jacqueline A M van Gaans-van den Brink; Alex-Mikael Barkoff; Qiushui He; Gerben Ferwerda; Pauline Versteegen; Guy A M Berbers; Alberto Orfao; Jacques J M van Dongen; Cristina Teodosio
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

5.  Radiotherapy-Induced Changes in the Systemic Immune and Inflammation Parameters of Head and Neck Cancer Patients.

Authors:  Katalin Balázs; Enikő Kis; Christophe Badie; Enikő Noémi Bogdándi; Serge Candéias; Lourdes Cruz Garcia; Iwona Dominczyk; Benjamin Frey; Udo Gaipl; Zsolt Jurányi; Zsuzsa S Kocsis; Eric Andreas Rutten; Géza Sáfrány; Piotr Widlak; Katalin Lumniczky
Journal:  Cancers (Basel)       Date:  2019-09-06       Impact factor: 6.639

6.  Systemic modulation of stress and immune parameters in patients treated for prostate adenocarcinoma by intensity-modulated radiation therapy or stereotactic ablative body radiotherapy.

Authors:  B Frey; J Mika; K Jelonek; L Cruz-Garcia; C Roelants; I Testard; N Cherradi; K Lumniczky; S Polozov; A Napieralska; P Widlak; U S Gaipl; C Badie; J Polanska; S M Candéias
Journal:  Strahlenther Onkol       Date:  2020-06-09       Impact factor: 3.621

7.  Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer.

Authors:  Elgin Hoffmann; Frank Paulsen; Philipp Schaedle; Daniel Zips; Cihan Gani; Hans-Georg Rammensee; Cécile Gouttefangeas; Franziska Eckert
Journal:  Cancer Immunol Immunother       Date:  2021-07-16       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.